Biogen Idec Oral MS Agent BG-12 Safety Takes Center Stage At Firm’s R&D Day
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec highlighted the safety profile of its oral multiple sclerosis compound BG-12 during its recent R&D Day.
You may also be interested in...
Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help
Tysabri’s REMS could prove to be a model for drugs with serious safety signals.
Tysabri Returns, But Biogen Idec’s Oral MS Drug Buy May Mean More
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.